Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AnHeart Starts Global Phase II Trial of mIDH1 Inhibitor for Brain Cancer

publication date: Sep 7, 2023

AnHeart Therapeutics, a New York-Hangzhou biotech, dosed the first patient in a global Phase II trial of safusidenib in patients with mutant isocitrate dehydrogenase 1 (mIDH1) glioma, a common brain cancer. Safusidenib is a novel, oral mIDH1 inhibitor. In a Phase I trial, it has shown high blood-brain barrier penetration along with anti-tumor activity in patients with recurrent IDH1-mutant gliomas. AnHeart acquired global rights (except Japan) to safusidenib in 2020 from Daiichi Sankyo soon after it in-licensed global rights from Daiichi Sankyo for AnHeart’s lead drug, a next-gen ROS1-inhibitor currently in pivotal Phase II trials for ROS1-positive NSCLC. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital